SGS Announces Appointments at New Facility in California
PTSM: Pharmaceutical Technology Sourcing and Management
SGS makes two senior appointments at its new GMP/GLP laboratory in Carson, California.
SGS Life Science Services reported two senior appointments at its new GMP/GLP laboratory in Carson, CA, which is due to open in the third quarter of 2014.
Marcella McSorley joins SGS as QA manager, and will have a role in the implementation of a quality management system at the new site. McSorley previously served as the director of quality control for Aaron Industries. SGS has also appointed Pojaman Zunggeemoge as microbiology manager. Zunggeemoge will focus on the management of the microbiology department at Carson and ensure the on-going compliance with SOPs. She joins SGS from Grifols Biologicals, where she was the QC microbiology supervisor.
The 7,500 ft2 Carson facility will offer microbiological testing and bioanalytical services in a GMP/GLP controlled environment. This will be SGS’s fifth North American site in addition to its facilities in Fairfield, NJ, Lincolnshire, IL, West Chester, PA, and Mississauga, ON.
Source: SGS Life Science Services
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
